阿奇霉素联合N-乙酰半胱氨酸对稳定期COPD患者血清GRO-α、MRpro-ADM水平的影响(1)
【摘要】 目的：研究阿奇霉素聯合N-乙酰半胱氨酸用于稳定期慢性阻塞性肺疾病(COPD)中的价值。方法：选择2017年1月-2018年5月本院收治的114例稳定期COPD患者，按照随机数字表法分为研究组与对照组，各57例。研究组给予阿奇霉素联合N-乙酰半胱氨酸治疗，对照组进行常规治疗。对比两组治疗前后血清生长调节致癌基因α(GRO-α)、肾上腺髓质素前体中段肽(MRpro-ADM)水平、炎性因子、肺功能与不良反应发生情况。结果：治疗后研究组GRO-α、MRpro-ADM均低于对照组(P<0.05);治疗后研究组白介素-8(IL-8)、C反应蛋白(CRP)及肿瘤坏死因子-α(TNF-α)均低于对照组(P<0.05);治疗后研究组FEV1、FVC及FEV1占预计值的百分比(FEV1% pred)均高于对照组(P<0.05);研究组不良反应发生率(5.26%)与对照组(8.77%)比较，差异无统计学意义(P>0.05)。
结论：阿奇霉素联合N-乙酰半胱氨酸治疗稳定期COPD可明显改善GRO-α、MRpro-ADM水平，降低炎症反应，提高肺功能，促进病情稳定，为预后提供保障。
【关键词】 肾上腺髓质素前体中段肽; 阿奇霉素; 稳定期慢性阻塞性肺病; 生长调节致癌
基因α; N-乙酰半胱氨酸
Effect of Azithromycin Combined with N-acetylcysteine on Serum GRO-αand MRpro-ADM Levels in Stable COPD Patients/ZHANG Xueyong，YANG Qingyu，LIU Yonggang，et al.//Medical Innovation of China，2019，16(21)：00-009
【Abstract】 Objective：To study the effect of Azithromycin combined with N-acetylcysteine in stable chronic obstructive pulmonary disease(COPD)patients.Method：114 patients with stable COPD from January 2017 to May 2018 treated in our hospital were selected and divided into study group and control group according to the random number table method，57 cases in each group.The study group was treated with Azithromycin combined with N-acetylcysteine，the control group was treated with conventional therapy.The serum levels of growth-regulated oncogene-α(GRO-α)，midregional fragment of pro-adrenomedullin(MRpro-ADM)，inflammatory factors，lung function and adverse reactions of two groups were compared before and after treatment.Result：GRO-α and MRpro-ADM in the study group after treatment were lower than those in the control group(P<0.05).IL-8(interleukin-8)，CRP(C-reactive protein)and TNF-α(tumor necrosis factor-α)after treatment in the study group were lower than those in the control group(P<0.05).The forced expiratory volume in one second(FEV1)，forced lung capacity(FVC)and the percentage of FEV1 in the estimated value(FEV1% pred)in the study group after treatment were higher than those in the control group(P<0.05).The incidence of adverse reactions in the study group(5.26%)was compared with that in the control group(8.77%)，the difference was not statistically significant(P>0.05).Conclusion：Azithromycin combined with N-acetylcysteine in the treatment of stable COPD can significantly improve GRO-αand MRpro-ADM levels，reduce the inflammatory response，increase the pulmonary function，promote the stability of the disease and provide guarantee for the prognosis., 百拇医药(张学勇 杨庆宇 刘永刚 孙宇)
结论：阿奇霉素联合N-乙酰半胱氨酸治疗稳定期COPD可明显改善GRO-α、MRpro-ADM水平，降低炎症反应，提高肺功能，促进病情稳定，为预后提供保障。
【关键词】 肾上腺髓质素前体中段肽; 阿奇霉素; 稳定期慢性阻塞性肺病; 生长调节致癌
基因α; N-乙酰半胱氨酸
Effect of Azithromycin Combined with N-acetylcysteine on Serum GRO-αand MRpro-ADM Levels in Stable COPD Patients/ZHANG Xueyong，YANG Qingyu，LIU Yonggang，et al.//Medical Innovation of China，2019，16(21)：00-009
【Abstract】 Objective：To study the effect of Azithromycin combined with N-acetylcysteine in stable chronic obstructive pulmonary disease(COPD)patients.Method：114 patients with stable COPD from January 2017 to May 2018 treated in our hospital were selected and divided into study group and control group according to the random number table method，57 cases in each group.The study group was treated with Azithromycin combined with N-acetylcysteine，the control group was treated with conventional therapy.The serum levels of growth-regulated oncogene-α(GRO-α)，midregional fragment of pro-adrenomedullin(MRpro-ADM)，inflammatory factors，lung function and adverse reactions of two groups were compared before and after treatment.Result：GRO-α and MRpro-ADM in the study group after treatment were lower than those in the control group(P<0.05).IL-8(interleukin-8)，CRP(C-reactive protein)and TNF-α(tumor necrosis factor-α)after treatment in the study group were lower than those in the control group(P<0.05).The forced expiratory volume in one second(FEV1)，forced lung capacity(FVC)and the percentage of FEV1 in the estimated value(FEV1% pred)in the study group after treatment were higher than those in the control group(P<0.05).The incidence of adverse reactions in the study group(5.26%)was compared with that in the control group(8.77%)，the difference was not statistically significant(P>0.05).Conclusion：Azithromycin combined with N-acetylcysteine in the treatment of stable COPD can significantly improve GRO-αand MRpro-ADM levels，reduce the inflammatory response，increase the pulmonary function，promote the stability of the disease and provide guarantee for the prognosis., 百拇医药(张学勇 杨庆宇 刘永刚 孙宇)